Compare Altria Group Inc (MO) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Twist Bioscience Corp — how do they compare? Altria Group Inc trades at $74.53 (market cap $124.67B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Altria Group Inc is far larger — about 22.9× Twist Bioscience Corp's market cap, and Altria Group Inc pays a 5.68% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| MO | TWST | |
|---|---|---|
Market Cap | $124.67B | $5.45B |
Sector | Consumer Staples | Health |
52-Week High | $74.66 | $102.88 |
52-Week Low | $54.72 | $24.16 |
Enterprise Value | $145.75B | $5.37B |
Dividend Yield | 5.68% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
